Sign In
Buy PTC
$139.72
-2.62 (-1.84%)
At Close: Jun 03, 2026
PTC Inc. (PTC) Is Up 3.15% in One Week: What You Should Know
01:00pm, Thursday, 24'th Jul 2025
Does PTC Inc. (PTC) have what it takes to be a top stock pick for momentum investors? Let's find out.
PTC Inc. (PTC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:07am, Wednesday, 23'rd Jul 2025
PTC Inc. (PTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results
04:30pm, Monday, 21'st Jul 2025
WARREN, N.J. , July 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2025 financial resu
Why PTC Inc. (PTC) is a Top Growth Stock for the Long-Term
10:45am, Wednesday, 16'th Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PTC Announces Startup Program to Accelerate the Future of Aerospace & Defense Innovation
08:30am, Wednesday, 16'th Jul 2025
Free access to Creo+, Onshape, Codebeamer+, and a startup package for Arena to enable startups to meet the speed, complexity, and compliance demands of modern aerospace and defense product development
PTC Inc. (PTC) Soars 17.7%: Is Further Upside Left in the Stock?
09:50am, Thursday, 10'th Jul 2025
PTC Inc. (PTC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
PTC Stock Pulls Back After Soaring on Report of Possible Autodesk Bid
07:29am, Thursday, 10'th Jul 2025
Shares of software company PTC ended Wednesday's session up 18%.
PTC to Announce Fiscal Q3'25 Results on Wednesday, July 30th, 2025
07:00am, Wednesday, 09'th Jul 2025
BOSTON , July 9, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) will release its fiscal 2025 third quarter results on Wednesday, July 30 th after the stock market closes. Senior management will host a live w
PTC's Onshape and Arena Selected by Nimble to Scale Superhumanoids that Power Next-Gen Autonomous Logistics
08:30am, Tuesday, 08'th Jul 2025
BOSTON , July 8, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that Nimble, a leader in AI robotics and autonomous logistics technology, is replacing its legacy computer-aided design (CAD),
PTC Unveils Arena SCI for Resilient Product Development
11:06am, Friday, 27'th Jun 2025
PTC debuts Arena SCI to tackle supply chain risk with AI, even as mounting debt highlights growing financial pressure.
PTC Launches Arena Supply Chain Intelligence to Help Manufacturers and Product Companies Mitigate Supply Chain Risks
08:30am, Tuesday, 24'th Jun 2025
New cloud-native supply chain offering delivers supply chain risk insights directly into product lifecycle management Arena SCI proactively monitors component risks and recommends alternative options
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
10:00am, Sunday, 22'nd Jun 2025
NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 19'th Jun 2025
WARREN, N.J. , June 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 16, 2025, the company approved non-statutory stock options to purchase an aggregate of
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
12:35pm, Wednesday, 18'th Jun 2025
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are a
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
10:00am, Tuesday, 17'th Jun 2025
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised
